These three biomolecular entities are responsible for signal transduction and are important drug targets. Therefore, in order to design more efficient drugs and drug delivery systems, a better understanding of the physicochemical interactions that govern biomembrane and protein interfaces is needed. The BRFAA partner has a significant track record in this area and can lead the efforts in this application area. Other partners that will contribute are the Bioinformatics Group of the International Scientific-Educational Center of the National Academy of Sciences of the Republic of Armenia and the Drug Discovery Laboratory, Faculty of Medicine, Bar-Ilan University in Israel. Molecular physics department of the Yerevan State University and Armenian-Indian Center of Excellence in ICT will investigate amyloid proteins for Alzheimer’s disease.